Entera Bio has entered into a research collaboration and license agreement with Amgen in inflammatory disease and other serious illnesses.    Entera will use its proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected. Amgen also has an option to select up to two additional programs to include in the collaboration. “We are excited to leverage our proprietary oral drug delivery platform in collaboration with...